[1]章海斌,王 练.基于糖酵解相关基因GFUS对三阴性乳腺癌疗效预测模型构建与验证[J].医学信息,2024,37(01):22-28，34.[doi:10.3969/j.issn.1006-1959.2024.01.004]
　ZHANG Hai-bin,WANG Lian.Construction and Validation of a Prediction Model for the Efficacy of Triple-negative Breast Cancer Based on the Glycolysis-related Gene GFUS[J].Journal of Medical Information,2024,37(01):22-28，34.[doi:10.3969/j.issn.1006-1959.2024.01.004]
点击复制

基于糖酵解相关基因GFUS对三阴性乳腺癌疗效预测模型构建与验证()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
37卷
期数:
2024年01期
页码:
22-28，34
栏目:
临床信息学
出版日期:
2024-01-01

文章信息/Info

Title:
Construction and Validation of a Prediction Model for the Efficacy of Triple-negative Breast Cancer Based on the Glycolysis-related Gene GFUS
文章编号:
1006-1959（2024）01-0022-08
作者:
章海斌; 王 练
（蚌埠医学院第一附属医院肿瘤内科1，中医科2，安徽 蚌埠 233000）
Author(s):
ZHANG Hai-bin; WANG Lian
(Department of Medical Oncology1,Department of Traditional Chinese Medicine2,the First Affiliated Hospitalof Bengbu Medical College,Bengbu 233000,Anhui,China)
关键词:
三阴性乳腺癌; GDP-L-岩藻糖合酶; 预后模型
Keywords:
Triple-negative breast cancer; GDP-L-amylose synthase; Prognostic model
分类号:
R737.9
DOI:
10.3969/j.issn.1006-1959.2024.01.004
文献标志码:
A
摘要:
目的 基于生物信息数据库信息探讨糖酵解相关基因GDP-L-岩藻糖合酶（GFUS）对三阴性乳腺癌（TNBC）预后情况的预测价值。方法 从癌症基因组图谱（TCGA）数据库获取TNBC基因表达信息，应用生物信息学方法分析GFUS在TNBC中的差异表达及预后差异，筛选与GFUS共表达基因建立预测TNBC预后模型并验证。结果 从TCGA数据库下载160例TNBC组织和113例正常组织的基因转录组数据，验证了GFUS在TNBC中的高表达与不良预后相关。基于GFUS共表达基因，通过COX回归分析得到3个与TNBC预后相关基因，以此构建模型。根据预后模型将外部数据集训练样本分为高风险组（45例）和低风险组（62例）。Kaplan-Meier生存分析显示，高风险组总生存情况低于低风险组，差异有统计学意义（P＜0.05）。结论 基于糖酵解相关基因GFUS建立的模型可有效预测TNBC预后情况，并为个体化治疗提供新思路。
Abstract:
Objective To explore the predictive value of glycolysis-related gene GDP-L-amylose synthase (GFUS) on the prognostic profile of triple-negative breast cancer (TNBC) based on bioinformatics database information.Methods The gene expression information of TNBC was obtained from the Cancer Genome Atlas (TCGA) database. The differential expression and prognostic differences of GFUS in TNBC were analyzed by bioinformatics methods. The co-expressed genes with GFUS were screened to establish a prognostic model for TNBC and verified.Results The gene transcriptome data of 160 TNBC tissues and 113 normal tissues were downloaded from the TCGA database, which verified that the high expression of GFUS in TNBC was associated with poor prognosis. Based on GFUS co-expressed genes, three genes related to TNBC prognosis were obtained by COX regression analysis to construct the model. According to the prognostic model, the external data set training samples were divided into high-risk group (45 cases) and low-risk group (62 cases). Kaplan-Meier survival analysis showed that the total survival of the high-risk group was lower than that of the low-risk group, and the difference was statistically significant (P<0.05).Conclusion The model based on the glycolysis-related gene GFUS can effectively predict the prognosis of TNBC and provide new ideas for individualized treatment.

参考文献/References:

[1]Yin L,Duan JJ,Bing XW,et al.Triple-negative breast cancer molecular subtyping and treatment progress[J].Breast Cancer Res,2020,22(1):61.[2]Lyons TG.Targeted Therapies for Triple-Negative Breast Cancer[J].Current Treatment Options in Oncology,2019,20(11):82.[3]Kizuka Y,Nakano M,Yamaguchi Y,et al.An Alkynyl-Fucose Halts Hepatoma Cell Migration and Invasion by Inhibiting GDP-Fucose-Synthesizing Enzyme FX, TSTA3[J].Cell Chemical Biology,2017,24(12):1467-1478.e5.[4]Paul S,Ghosh S,Kumar S.Tumor glycolysis, an essential sweet tooth of tumor cells[J].Seminars in Cancer Biology,2022,86(Pt 3):1216-1230.[5]岑宸翊,胡恋,王赵劼,等.三阴性乳腺癌细胞中线粒体功能障碍对糖代谢途径的影响[J].现代肿瘤医学,2023,31(1):33-38.[6]Wu Z,Wu J,Zhao Q,et al.Emerging roles of aerobic glycolysis in breast cancer[J].Clin Transl Oncol,2020,22(5):631-646.[7]Leal Quirino MW,Albuquerque APB,de Souza MFD,et al.FUCA2 and TSTA3 expression in gastric cancer:candidate biomarkers of malignant transformation[J].Folia Histochem Cytobiol,2022,60(4):335-343.[8]Zhang L,Gao Y,Zhang X,et al.TSTA3 facilitates esophageal squamous cell carcinoma progression through regulating fucosylation of LAMP2 and ERBB2[J].Theranostics,2020,10(24):11339-11358.[9]Feichtinger RG,Hullen A,Koller A,et al.A spoonful of L-fucose-an efficient therapy for GFUS-CDG,a new glycosylation disorder[J].EMBO Molecular Medicine,2021,13(9):e14332.[10]Howard FM,Olopade OI.Epidemiology of Triple-Negative Breast Cancer: A Review[J].Cancer J,2021,27(1):8-16.[11]Warburg O.On the origin of cancer cells[J].Science,1956,123(3191):309-314.[12]李玉环.PKM2在肿瘤代谢及进展中的作用[J].安徽医科大学学报,2018,53(5):818-821.[13]胡沥予,李航真,方天星,等.低氧环境对三阴性乳腺癌细胞糖代谢途径的重编程[J].中国生物化学与分子生物学报,2022,38(7):936-948.[14]Bianchini G,Dd Angelis C,Licata L,et al.Treatment landscape of triple-negative breast cancer-expanded options, evolving needs[J].Nat Rev.Clin Oncol,2022,19(2):91-113.[15]Derakhshan F,Reis-Filho JS.Pathogenesis of Triple-Negative Breast Cancer[J].Annual Review of Pathology,2022,17:181-204.[16]马怡君,周彩婷,韩微,等.N端去糖基化修饰对三阴型乳腺癌中PD-L1蛋白表达的影响[J].临床与实验病理学杂志,2022,38(7):879-882.[17]钟恋君,王进京,郑洪.三阴型乳腺癌间质肿瘤浸润淋巴细胞CD4、CD8、Foxp3和PD-L1表达的临床病理意义[J].临床与实验病理学杂志,2022,38(3):278-283,288.[18]Schreier A,Zappasodi R,Serganova I,et al.Facts and Perspectives: Implications of tumor glycolysis on immunotherapy response in triple negative breast cancer[J].Frontiers in Oncology,2022,12:1061789.[19]Lei X,Lei Y,Li JK,et al.Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy[J].Cancer Lett,2020,470:126-133.[20]Sadeghalvad M,Mohammadi-Motlagh HR,Rezaei N.Immune microenvironment in different molecular subtypes of ductal breast carcinoma[J].Breast Cancer Res Treat,2021,185(2):261-279.

相似文献/References:

[1]徐忆芳,罗秀丽.基于数据挖掘的罗秀丽教授治疗三阴性乳腺癌的临床经验研究[J].医学信息,2019,32(20):159.[doi:10.3969/j.issn.1006-1959.2019.20.050]
　XU Yi-fang,LUO Xiu-li.Professor Luo Xiuli's Clinical Experience in Treating Triple-negative Breast Cancer Based on Data Mining[J].Journal of Medical Information,2019,32(01):159.[doi:10.3969/j.issn.1006-1959.2019.20.050]
[2]贾秀鹏,蒙伶俐,李海莉,等.三阴性乳腺癌与非三阴性乳腺癌组织中PD-1、PD-L1、FOXP3的差异表达及其临床意义[J].医学信息,2021,34(21):7.[doi:10.3969/j.issn.1006-1959.2021.21.002]
　JIA Xiu-peng,MENG Ling-li,LI Hai-li,et al.Differential Expression and Clinical Significance of PD-1, PD-L1 and FOXP3 in Triple-negative Breast Cancer and Non-triple-negative Breast Cancer Tissues[J].Journal of Medical Information,2021,34(01):7.[doi:10.3969/j.issn.1006-1959.2021.21.002]
[3]涂 强.lncRNAs在三阴性乳腺癌发生发展中的作用[J].医学信息,2020,33(10):37.[doi:10.3969/j.issn.1006-1959.2020.10.011]
　TU Qiang.The Role of lncRNAs in the Development of Triple Negative Breast Cancer[J].Journal of Medical Information,2020,33(01):37.[doi:10.3969/j.issn.1006-1959.2020.10.011]
[4]石少庆,宋丽丽.紫杉醇联合卡铂方案在三阴性乳腺癌新辅助化疗中的治疗效果及对患者病理变化的影响[J].医学信息,2023,36(02):145.[doi:10.3969/j.issn.1006-1959.2023.02.031]
　SHI Shao-qing,SONG Li-li.The Therapeutic Effect of Paclitaxel Combined with Carboplatin in Neoadjuvant Chemotherapy for Triple Negative Breast Cancer and its Effect on Pathological Changes[J].Journal of Medical Information,2023,36(01):145.[doi:10.3969/j.issn.1006-1959.2023.02.031]
[5]杨 洁,廖 萍,黄志平,等.二维超声及弹性成像预测三阴性乳腺癌新辅助化疗效果的价值[J].医学信息,2021,34(13):173.[doi:10.3969/j.issn.1006-1959.2021.13.048]
　YANG Jie,LIAO Ping,HUANG Zhi-ping,et al.The Value of Two-dimensional Ultrasound and Elastography in Predicting the Effect of Neoadjuvant Chemotherapy for Triple-negative Breast Cancer[J].Journal of Medical Information,2021,34(01):173.[doi:10.3969/j.issn.1006-1959.2021.13.048]

更新日期/Last Update: 1900-01-01